التفاصيل البيبلوغرافية
| العنوان: |
Conversion surgery for hepatocellular carcinoma after tyrosine kinase inhibitor treatment |
| المؤلفون: |
Shun Kaneko, Kaoru Tsuchiya, Yutaka Yasui, Yuki Tanaka, Kento Inada, Shun Ishido, Sakura Kirino, Koji Yamashita, Yuka Hayakawa, Tsubasa Nobusawa, Hiroaki Matsumoto, Tatsuya Kakegawa, Mayu Higuchi, Kenta Takaura, Shohei Tanaka, Chiaki Maeyashiki, Nobuharu Tamaki, Yuka Takahashi, Hiroyuki Nakanishi, Takumi Irie, Shun‐Ichi Ariizumi, Masayuki Kurosaki, Namiki Izumi |
| المصدر: |
JGH Open, Vol 6, Iss 5, Pp 301-308 (2022) |
| بيانات النشر: |
Wiley, 2022. |
| سنة النشر: |
2022 |
| المجموعة: |
LCC:Diseases of the digestive system. Gastroenterology |
| مصطلحات موضوعية: |
albumin–bilirubin score, conversion surgery, hepatocellular carcinoma, lenvatinib, sorafenib, tyrosine kinase inhibitor, Diseases of the digestive system. Gastroenterology, RC799-869 |
| الوصف: |
Abstract Background and Aim Conversion surgery (CS), which aims to cure after systematic therapy, is only scarcely reported in the field of hepatocellular carcinoma (HCC). However, advancements in systemic therapy for HCC are expected to increase the candidates eligible for CS because of the higher response rate. The aim of this study was to clarify the characteristics of patients who underwent CS after tyrosine kinase inhibitor (TKI) therapy. Methods In all, 364 patients who were treated with first‐line sorafenib (SOR; n = 292) and lenvatinib (LEN; n = 72) from July 2009 to October 2020 were retrospectively enrolled. The endpoint of this analysis was overall survival (OS), and factors associated with CS are revealed. Results Six patients underwent CS after TKI therapy, and of these four (1.4%) and two (2.7%) patients received SOR and LEN, respectively. At baseline, patients who underwent CS were significantly younger (median 52 [range, 46–83] years of age, P = 0.019), and their etiology included viral hepatitis, especially hepatitis B virus (HBV) (P = 0.049). Improvements or maintenance of preoperative modified albumin–bilirubin grade from baseline were observed in five (83.3%) patients, and partial radiologic response was observed in four (66.7%) patients. The median OS and 3‐year survival rate of patients treated with CS were “not reached” and 80.0%, respectively. Conclusion The patients who underwent CS after TKI therapy for HCC experienced long survival, were relatively young, and exhibited radiologic response to TKIs, and their liver function was either maintained or improved. Therefore, CS may lead to a better prognosis in patients with advanced HCC. |
| نوع الوثيقة: |
article |
| وصف الملف: |
electronic resource |
| اللغة: |
English |
| تدمد: |
2397-9070 |
| Relation: |
https://doaj.org/toc/2397-9070 |
| DOI: |
10.1002/jgh3.12735 |
| URL الوصول: |
https://doaj.org/article/896f5a83aa354941b6e45e2c416ab912 |
| رقم الانضمام: |
edsdoj.896f5a83aa354941b6e45e2c416ab912 |
| قاعدة البيانات: |
Directory of Open Access Journals |
Full Text Finder